End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
15.55
CNY
|
+9.82%
|
|
+5.35%
|
+45.87%
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,591
|
7,097
|
7,477
|
10,907
|
-
|
-
|
Enterprise Value (EV)
1 |
3,591
|
7,097
|
7,477
|
10,907
|
10,907
|
10,907
|
P/E ratio
|
40.8
x
|
39.7
x
|
19.4
x
|
19.9
x
|
16.4
x
|
13.4
x
|
Yield
|
-
|
-
|
4.22%
|
4.05%
|
4.95%
|
6.05%
|
Capitalization / Revenue
|
-
|
-
|
3.85
x
|
4.15
x
|
3.37
x
|
2.69
x
|
EV / Revenue
|
-
|
-
|
3.85
x
|
4.15
x
|
3.37
x
|
2.69
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
2.74
x
|
3.58
x
|
3.32
x
|
3.04
x
|
Nbr of stocks (in thousands)
|
608,625
|
608,625
|
701,387
|
701,387
|
-
|
-
|
Reference price
2 |
5.900
|
11.66
|
10.66
|
15.55
|
15.55
|
15.55
|
Announcement Date
|
3/9/21
|
3/9/22
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1,942
|
2,629
|
3,232
|
4,056
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
448.7
|
640
|
775
|
945
|
Operating Margin
|
-
|
-
|
-
|
23.1%
|
24.34%
|
23.98%
|
23.3%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
3,409
|
446.6
|
634
|
769
|
939
|
Net income
1 |
87.96
|
178.7
|
2,917
|
382.9
|
546.5
|
663.8
|
810.9
|
Net margin
|
-
|
-
|
-
|
19.71%
|
20.79%
|
20.54%
|
19.99%
|
EPS
2 |
0.1445
|
0.2937
|
-
|
0.5500
|
0.7800
|
0.9500
|
1.160
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.4500
|
0.6300
|
0.7700
|
0.9400
|
Announcement Date
|
3/9/21
|
3/9/22
|
3/14/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
13.8%
|
17.9%
|
20.2%
|
22.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
10.5%
|
13.8%
|
14.8%
|
15.8%
|
Assets
1 |
-
|
-
|
-
|
3,635
|
3,960
|
4,485
|
5,132
|
Book Value Per Share
2 |
-
|
-
|
-
|
3.890
|
4.340
|
4.690
|
5.110
|
Cash Flow per Share
2 |
-
|
-
|
-
|
0.4100
|
0.9500
|
0.9900
|
1.160
|
Capex
1 |
-
|
-
|
-
|
129
|
17
|
62
|
42
|
Capex / Sales
|
-
|
-
|
-
|
6.66%
|
0.65%
|
1.92%
|
1.04%
|
Announcement Date
|
3/9/21
|
3/9/22
|
3/14/23
|
3/12/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +45.87% | 1.5B | | +14.19% | 5B | | -33.68% | 3.52B | | -0.74% | 3.11B | | -24.38% | 2.65B | | -9.94% | 2.31B | | +39.98% | 1.86B | | +40.95% | 1.37B | | -14.41% | 1.41B | | -25.24% | 1.31B |
Alternative Medicine
|